- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Estetrol effective in alleviating vasomotor symptoms among postmenopausal women.
![Estetrol effective in alleviating vasomotor symptoms among postmenopausal women. Estetrol effective in alleviating vasomotor symptoms among postmenopausal women.](https://medicaldialogues.in/h-upload/2023/05/04/750x450_208857-untitled-design-28.webp)
A recent study has mentioned that Women receiving estetrol 15 mg have reduced vaginal atrophy. They also added that Estetrol 15 mg reduces the intensity score for vaginal dryness and dyspareunia.
The study has addressed the benefits of using hormone estetrol 15 mg once daily for managing menopausal symptoms other than vasomotor symptoms. This research is published in MENOPAUSE.
Estetrol 15 mg was associated with estrogenic effects in the vagina and a reduction in atrophy signs, according to them.
Researchers in this study reported the effects of Estetrol on the vaginal epithelial cell maturation index and maturation value, genitourinary syndrome of menopause score and the Menopause Rating Scale to assess health-related quality of life using estetrol 15 mg.
The research summary includes the following considerations:
- The study had 257 postmenopausal women with a mean age of 54.2 years.
- The doses of estetrol 2.5 mg, 5 mg, 10 mg,15 mg and placebo once daily for 12 weeks were assigned to 52, 47, 54, 49 and 55 women, respectively.
- The decrease in parabasal and intermediate vaginal epithelial cells among those receiving estetrol 2.5 mg, 5mg, 10 mg and 15 mg was –12.3 and –7.6, –20.7 and –11.9, –15.6 and –21.8, and –23.4 and –13.4, respectively.
- There was an increase in superficial cells with values of 19.9, 32.6, 37.4, and 36.8, respectively.
- Women on estetrol 15 mg had a least square mean change of –10.81%, -20.96 % and 34.17 (increase) in parabasal, intermediate, and superficial cells, respectively.
- 15 mg estetrol 15 mg decreased the least square mean intensity score for vaginal dryness and dyspareunia.
- Using estetrol 15 mg had fewer reports of vaginal dryness by 41% and reports of dyspareunia by 50%.
Concluding further, they wrote, There was an overall decrease in Menopause Rating Scale score by a least square mean of –3.1 with estetrol 15 mg and across other estetrol doses was associated with a decreased frequency and severity of vasomotor symptoms.
We found that Estetrol 15 mg has benefits in relieving postmenopausal symptoms in women, which is a cause of distress among them.
Further reading:
Gaspard U, et al. Menopause. 2023;doi:10.1097/GME.0000000000002167.
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751